(NASDAQ: TERN) Terns Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 61.98%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.85%.
Terns Pharmaceuticals's earnings in 2026 is -$94,435,000.On average, 13 Wall Street analysts forecast TERN's earnings for 2026 to be -$109,284,790, with the lowest TERN earnings forecast at -$135,948,405, and the highest TERN earnings forecast at -$75,667,016. On average, 11 Wall Street analysts forecast TERN's earnings for 2027 to be -$134,723,320, with the lowest TERN earnings forecast at -$160,666,297, and the highest TERN earnings forecast at -$87,017,068.
In 2028, TERN is forecast to generate -$147,010,203 in earnings, with the lowest earnings forecast at -$196,860,353 and the highest earnings forecast at -$80,396,205.